About Uperp
Uperp was a Healthcare company based in Chennai (India) founded in 2013. It offers liquid-based cytology tests for effective cervical cancer screening. It operates on a B2B model. The company has 830 employees. Its Indian entity Regenix Drugs Limited reported revenue of ₹177 Cr. The company is recorded as dissolved. Its focus areas include Medical Diagnostics, Cancer Screening and Cytology Testing. Its competitors include Aindra and bioLOCKEY Healthworks; 2 of its 2 listed competitors have raised funding.
Company details
Uperp, founded in 2013 in Chennai, India, focuses on providing healthcare solutions, medical diagnostics, cancer screening, and cytology testing. Offers liquid-based cytology tests for effective cervical cancer screening. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
- Headquarters Chennai, India
- Employees 830
- SectorsHealthcare
- Website uprepindia.com
- Legal Name Regenix Drugs Limited
- Date of Incorporation 10 May, 2007
- Jurisdiction Chennai, Tamil Nadu, India
- Annual Revenue₹177 Cr
FY 2024 · +9% YoY
- Net Profit₹5.20 Cr
FY 2024 · 3% margin
- EBITDA₹9.77 Cr
FY 2024 · 5% margin
- Employee Count830
Associated legal entities of Uperp
Uperp operates through Regenix Drugs Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Regenix Drugs Limited CIN U24232TN2007PLC063446 | Active | 10 May 2007 | Chennai, Tamil Nadu | ₹177 Cr | 830 | 13 | View details |
Board of directors of Regenix Drugs Limited (Uperp)
Regenix Drugs Limited is the primary company behind Uperp. The board of Regenix Drugs Limited currently have 11 directors; the longest-serving is Ramamurthy Ayyavuthevar, appointed in 2007. 24 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ramamurthy Ayyavuthevar DIN 00446203 | Managing Director | 30 Jun 2007 | 19 yrs 4 mo | Regenix Drugs Limited |
| Gunasekaran Raju DIN 01951733 | Director | 29 Sep 2007 | 19 yrs 1 mo | Regenix Drugs Limited |
| Govindarajan Venkatakrishna DIN 02159359 | Director | 20 Mar 2010 | 16 yrs 7 mo | Regenix Drugs Limited |
| Malathi Ramamurthy DIN 01965601 | Director | 15 Apr 2012 | 14 yrs 6 mo | Regenix Drugs Limited |
| Ayyamperumal DIN 08545531 | Director | 26 Aug 2019 | 7 yrs 2 mo | Regenix Drugs Limited |
| Srividhya DIN 11057425 | Nodal Officer | 29 Nov 2019 | 6 yrs 11 mo | Regenix Drugs Limited |
| Krishanamoorthy Nirosha DIN 09056949 | Whole-time director | 21 Jun 2021 | 5 yrs 4 mo | Regenix Drugs Limited |
| Guhan Ramamurthy DIN 09057147 | Director | 21 Jun 2021 | 5 yrs 4 mo | Regenix Drugs Limited |
| Akshay Arvind DIN 05355266 | Director | 25 Sep 2022 | 4 yrs 1 mo | Regenix Drugs Limited |
| Balaji Ramamurthy DIN 09350272 | Whole-time director | 01 Oct 2022 | 4 yrs 1 mo | Regenix Drugs Limited |
| Radhakrishnan Venu Murali DIN 02285294 | Director | 24 Sep 2023 | 3 yrs 1 mo | Regenix Drugs Limited |
Financials of Uperp
Figures of Regenix Drugs Limited, the primary company behind Uperp, for FY 2024. Revenue was ₹177 Cr (+9% year on year). Net profit was ₹5.20 Cr (3% margin). EBITDA was ₹9.77 Cr (5% margin). Revenue has grown at a compounded annual rate of +5442% over three years and +10% over five years.
- ₹177 CrRevenue · FY 2024 · +9% YoY
- ₹5.20 CrNet profit · 3% margin
- ₹9.77 CrEBITDA · 5% margin
- ₹18.08 CrPaid-up capital
- 830Employees (provident fund records)
- +5442%Revenue CAGR, 3 years
- +10%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Regenix Drugs Limited are on its company page.
Detailed financial statements for Uperp
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Uperp
Uperp has 2 listed competitors in our database, 2 of them funded. They include Aindra and bioLOCKEY Healthworks.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aindra.in | 2012 | Bengaluru, India | $304,345 | AI-powered systems for cervical cancer detection are provided. | ||
| biolockey.com | 2023 | Bengaluru, India | $143,228 | Point-of-care diagnostics and biologics are developed via Nanobody platform. |
Detailed competitors of Uperp
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Uperp
Uperp was founded in 2013.
Uperp is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.
Uperp has 830 employees.
The primary company behind Uperp, Regenix Drugs Limited, reported revenue of ₹177 Cr for FY 2024, up 9% year on year.
Uperp, founded in 2013 in Chennai, India, focuses on providing healthcare solutions, medical diagnostics, cancer screening, and cytology testing. Offers liquid-based cytology tests for effective cervical cancer screening. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Uperp's top competitors include Aindra and bioLOCKEY Healthworks.
Uperp operates through Regenix Drugs Limited.
The legal entities of Uperp currently have 11 directors, including Malathi Ramamurthy, Ayyamperumal, Krishanamoorthy Nirosha and others.